Cytomx Therapeutics Inc. CEO Sean McCarthy told BioWorld that the longish hiatus between deals broken by the tie-up with Astellas Pharma Inc. was “very deliberate. Over that period of time, we were generating our first clinical data to get experience with how the technology works in cancer patients with our first two lead programs,” both of which have reached the phase II stage. Read More
BEIJING – Cell therapies specialist Nanjing Iaso Biotherapeutics Co. Ltd. pocketed $60 million in a series funding B round to advance its CT-103A, an anti-BCMA CAR T therapy candidate for multiple myeloma, among other plans. Read More
BEIJING – Shanghai Junshi Biosciences Ltd. is developing neutralizing antibodies as a potential treatment for COVID-19, and the program will move on to clinical trials soon. Meanwhile, the biotech is set to launch a pre-revenue IPO on Shanghai’s STAR market. Read More
PERTH, Australia – As Australia closes its borders to all non-citizens and non-residents, it looks within the country for solutions to manage the worsening COVID-19 pandemic. Read More
Business as usual only three months ago has transformed into health care industry overdrive as biopharma and med-tech companies scramble to test and scale-up treatments, vaccines and diagnostics to address COVID-19. Read More
BEIJING – Cancer and autoimmune specialist Innocare Pharma Ltd., of Beijing, made a strong debut to raise $288 million on the Hong Kong Stock Exchange (HKEX) on March 23, marking the second biggest IPO in the city since the beginning of this year. Read More
HONG KONG – Korean biopharma Celltrion Inc. said it’s halfway through the process of creating a super antibody to reign in the COVID-19 novel coronavirus that has claimed almost 13,000 lives globally. Read More
BEIJING – China was the first country to face serious disruptions in clinical trials caused by COVID-19, and policy advocates in the country moved quickly to identify lessons for future outbreaks. Read More
BEIJING – The COVID-19 pandemic has temporarily impacted partnerships and investment opportunities, but it has also prompted other forms of collaboration within the biotech community. Read More
Targeting glycosylated PD-1 immune checkpoint may be a promising new cancer immunotherapeutic strategy, according to a collaborative study led by Taiwanese researchers, which was reported online in Cancer Research. Read More
DUBLIN – The Genentech arm of Roche Holding AG plans to move its interleukin-6 inhibitor, Actemra, into a global phase III trial in patients with severe pneumonia associated with COVID-19 infection. Read More
New hires and promotions in the biopharma industry in Asia-Pacific, including: Epimab Biotherapeutics, I-Mab Biopharma, Sumitomo Dainippon Pharma. Read More
The latest global regulatory news, changes and updates affecting biopharma, including: 340B Health, Department of Health and Human Services, FDA, Health Resources and Services Administration, Institute for Clinical and Economic Review, Medicines and Healthcare products Regulatory Agency. Read More
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Algernon, Cytodyn, Genentech, Humanigen, Immutep, Inxmed (Shanghai) Co., Recce. Read More
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Anheart, Applied DNA Sciences, Astrazeneca, Bellerophon, Can-Fite, Cansino Biologics, Cytodyn, Genentech, Hansoh, Merck, Novartis, Synairgen, Takis. Read More
